drugset / Trial / NCT03388593
Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate efficacy of rhNRG-1 in reducing the death rate of heart failure subjects with baseline NT-proBNP level between 600 pg/ml and 1700 pg/mL and NYHA class II to III.
Timeline
- Start
- 2018-07-23
- Primary completion
- 2026-02
- Completion
- 2026-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HUMAN NEUREGULIN-1 RECOMBINANT (177-237) | Protein / enzyme biologic | 0.8 ug/kg | Intravenous |